Sign in

You're signed outSign in or to get full access.

Jeff Thramann

Executive Chairman at Aclarion
Executive
Board

About Jeff Thramann

Jeffrey Thramann, M.D., is Executive Chairman and Director at Aclarion (ACON), serving as a director since 2020, Executive Director beginning March 2021, and transitioning to Executive Chairman at the April 21, 2022 IPO; age 60 as of April 30, 2025, with responsibilities spanning strategic vision, capitalization, governance, investor relations, and senior leadership recruitment . He completed neurosurgical residency and a complex spinal reconstruction fellowship at Barrow Neurological Institute, earned an M.D. from Cornell University Medical College, and a B.S. in electrical engineering management from the U.S. Military Academy at West Point; he is the named inventor on over 100 U.S. and international patents . Company-level TSR, revenue growth, and EBITDA growth linked to his tenure are not disclosed in these filings.

Past Roles

OrganizationRoleYearsStrategic Impact
Boulder Neurosurgical AssociatesFounder and Senior Partner2001–2008Built a neurosurgical practice in Boulder County, Colorado .
Lanx, LLCFounder and Chairman2002–2013 (sold to Biomet in Nov 2013)Innovated the interspinous process fusion space with patented Aspen product; exit to Biomet .
ProNerve, LLCFounder and Chairman2006–2012 (sold to Waud Capital Partners)Intraoperative neurophysiological monitoring during high-risk neuro/spine surgeries .
U.S. RadiosurgeryFounder and ChairmanPre-2011–2011 (sold to Alliance Healthcare Services in Apr 2011)Grew to largest U.S. provider of robotic CyberKnife radiosurgical treatments .

External Roles

OrganizationRoleYearsStrategic Impact
Auddia Inc. (NASDAQ: AUUD)Founder and Executive Chairman2012–presentAI platform reinventing audio experiences across radio and podcast; technology leadership and board governance .

Fixed Compensation

MetricFY 2023FY 2024
Base Salary ($)$300,000 $300,000
Target Bonus (%)Not disclosedNot disclosed
Actual Bonus Paid ($)$33,375 (approved June 2024) $80,625 (approved January 2025)
All Other Compensation ($)$0 $444 (Colorado FAMLI tax)
Total Compensation ($)$333,375 $381,069

Notes: Aclarion’s program emphasizes base, bonus, and equity incentives, but no stock or option awards were granted to Thramann in 2023–2024 .

Performance Compensation

  • Annual cash bonus amounts for 2023 and 2024 are disclosed, but the underlying performance metrics, weightings, targets, and payout formulas are not detailed in the proxy; the company states a pay-for-performance philosophy and utilizes bonuses and equity incentives generally .
  • The 2022 Equity Incentive Plan allows performance-based cash awards and a broad set of performance goals, with the Compensation Committee able to adjust for unusual/nonrecurring items; specific NEO KPIs for Thramann are not disclosed .

Equity Ownership & Alignment

ItemDetail
Beneficial ownership (May 9, 2025)10 shares; <1% of outstanding (582,371 shares outstanding) .
Beneficial ownership (Mar 31, 2025)10 shares; <1%; consistent with proxy .
Options – Thramann grant1,204,819 shares pre-splits; 8 shares post-2024/2025 stock splits; exercise price $1.94 per share ($280,756.80 post-split); 10-year term; vested on IPO date April 21, 2022 .
Options/RSUs outstanding company-wideAs of April 30, 2025: 4 options outstanding; no RSUs outstanding under the 2022 Plan .
Equity plan reserve and “evergreen”Plan features an evergreen increase (5% of prior year-end outstanding shares); details reiterated in 10-K and proxy .
Pledging/Hedging PolicyOfficers and directors prohibited from hedging and pledging company securities; margin accounts discouraged; preclearance and trading windows required .
Rule 10b5-1 plansPermitted; none adopted by directors or executive officers during 2024 .
Director fees for Exec ChairExecutive Chairman does not receive director compensation .

Interpretation: Severe reverse stock splits materially reduced absolute share counts, making option economics reflect consolidated/share-equivalent figures; executive prohibitions on pledging and derivatives reduce misalignment risk .

Employment Terms

  • Employment Agreement: Effective March 1, 2021 (executed June 15, 2021) for the Executive Director role; $25,000/month salary; transitioned to Executive Chairman at IPO; Thramann Options granted with 10-year term and full vest on IPO date .
  • At-will employment: Executive Director/Executive Chairman roles characterized as at-will in the agreement .
  • Severance/Change-of-Control: Specific severance for Thramann not disclosed. The 2022 Plan states unvested awards do not automatically vest upon change-of-control unless the Administrator decides; Administrator may accelerate vesting at discretion, including in connection with a change-in-control .
  • Clawback policy: Effective December 1, 2023; audit committee determined no recoveries were required (no performance-based compensation tied to filed financials during the lookback) .
  • Trading compliance: Preclearance, defined trading windows, and prohibition on hedging/pledging for officers/directors; 10b5-1 permitted but none in 2024 .

Board Governance

  • Board composition and independence: Seven directors; independent directors comprise a majority; Thramann (Executive Chairman), CEO Brent Ness, and David Neal are not independent .
  • Lead Independent Director: William Wesemann serves as Lead Independent Director due to a non-independent chair (Thramann) .
  • Committees and membership (2024 activity shown):
    • Audit Committee: Chair Stephen Deitsch; Members Breidbart, Wesemann; met 5 times; Deitsch designated audit committee financial expert .
    • Compensation Committee: Chair Wesemann; Members Amanda Williams, Breidbart; met 2 times; all independent members .
    • Nominating & Corporate Governance Committee: Chair Amanda Williams; Members Wesemann, Breidbart; met 1 time; all independent .
  • Attendance: Each director attended at least 75% of board and committee meetings in 2024; Board held 6 meetings .
  • Director compensation (non-employee): Annual cash—$25,000 board retainer; $15,000 Audit Chair; $5,000 per committee membership; Exec Chairman and CEO do not receive director fees .

Director Compensation (For reference)

NameFees Earned or Paid in Cash ($)Stock Awards ($)Option Awards ($)All Other Compensation ($)Total ($)
Scott Breidbart40,000 0 0 0 40,000
Stephen Deitsch45,000 0 0 0 45,000
David Neal25,000 0 0 0 25,000
William Wesemann40,000 0 0 0 40,000
Amanda Williams35,000 0 0 0 35,000

Other Directorships & Interlocks

  • Thramann is Executive Chairman of Auddia Inc. (NASDAQ: AUUD) .
  • Stephen Deitsch is a director and audit committee chair at Auddia and sits on Aclarion’s board and audit committee as chair, creating governance network ties between Aclarion and Auddia .

Compensation Structure Analysis

  • Mix shift: For Thramann, no equity grants in 2023–2024; compensation was base salary plus cash bonus and minimal “other,” implying a higher near-term cash mix and potentially lower fresh equity-linked pay over these two fiscal years .
  • Equity plan controls: Plan prohibits option repricing/cash exchange of in-the-money options without shareholder approval; Administrator controls award terms, can accelerate vesting, and maintain non-transferability except as permitted .
  • Grant timing: Company does not time equity awards around material non-public information; in 2024, no NEO equity grants were made adjacent to quarterly/annual filings .
  • Advisor independence: Compensation Committee evaluates and assesses compensation advisors per Nasdaq independence standards .

Related Party Transactions

  • The company reported no related person transactions in 2024 and maintains an audit-committee-administered related person transaction policy .

Risk Indicators & Red Flags

  • Dual role concerns: Executive Chairman role is non-independent; board mitigates with a Lead Independent Director and independent committees .
  • Pledging/hedging risk: Prohibited for officers/directors, reducing misalignment/forced-sale risk; trading windows and preclearance enforced .
  • Clawback readiness: Policy effective Dec 1, 2023; no recoveries required during review period; demonstrates compliance posture .
  • Equity plan COC mechanics: No automatic vesting on change-of-control; acceleration discretionary—less executive-protective than single/double-trigger mandates, reducing deal-related windfalls risk .
  • Share structure dynamics: Reverse stock splits significantly changed share counts and increased authorized-but-unissued shares, potentially affecting dilution calculus and option strike economics; board weighs liquidity and listing concerns vs. negative investor perceptions .

Equity Ownership & Alignment Details

MetricValue
Shares Outstanding (May 9, 2025)582,371
Thramann Beneficial Ownership (shares / %)10 shares; <1%
Options – VestingThramann Options vested on IPO date April 21, 2022; 10-year term
Options – Company Outstanding (Apr 30, 2025)4 options; 0 RSUs under 2022 Plan
Equity Plan EvergreenAnnual increase up to 5% of prior year-end outstanding shares

Investment Implications

  • Alignment: With no new equity awards in 2023–2024 for Thramann and very small post-split beneficial holdings, near-term selling pressure appears limited in magnitude; pledging/hedging prohibitions further align behavior with shareholders, and any 10b5-1 selling would be preplanned and compliant .
  • Retention: Immediate vesting of Thramann’s legacy option grant at IPO reduces unvested incentive “hooks”; retention hinges on role scope, cash compensation, and future equity policy changes rather than vesting overhang .
  • Governance quality: Independence structure is adequate (independent committees, Lead Independent Director) despite a non-independent chair; attendance and meeting cadence support oversight; committee responsibilities align with Nasdaq/SEC standards .
  • Deal dynamics: Discretionary COC vesting limits automatic executive windfalls, potentially favoring shareholder economics in strategic transactions relative to companies with generous double-trigger acceleration .
  • Pay-for-performance transparency: Lack of disclosed NEO performance metrics and bonus scorecards limits external assessment of pay-for-performance rigor; monitoring Compensation Committee disclosures and any future CD&A enhancements is warranted .

Citations: